A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis

DSpace/Manakin Repository

A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis

Citable link to this page


Title: A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis
Author: Alvarez, James V.; Mukherjee, Neelanjan; Chakravarti, Arnab; Robe, Pierre; Zhai, Gary; Chakladar, Abhijit; Loeffler, Jay S; Black, Peter McLaren; Frank, David A.

Note: Order does not necessarily reflect citation order of authors.

Citation: Alvarez, James V., Neelanjan Mukherjee, Arnab Chakravarti, Pierre Robe, Gary Zhai, Abhijit Chakladar, Jay Loeffler, Peter Black, and David A. Frank. 2007. A STAT3 gene expression signature in gliomas is associated with a poor prognosis. Translational Oncogenomics 2: 99-105.
Full Text & Related Files:
Abstract: Gliomas frequently display constitutive activation of the transcription factor STAT3, a protein that is known to be able to mediate neoplastic transformation. STAT3 regulates genes that play a central role in cellular survival, proliferation, self-renewal, and invasion, and a cohort of STAT3 target genes have been found that are commonly coexpressed in human cancers. Thus, these genes likely subserve the transforming ability of constitutively activated STAT3. To determine whether the coordinated expression of STAT3 target genes is present in a subset of human gliomas, and whether this changes the biology of these tumors in patients, gene expression analysis was performed in four distinct human glioma data sets for which patient survival information was available. Coordinate expression of STAT3 targets was significantly associated with poor patient outcome in each data set. Specifically, patients with tumors displaying high expression of STAT3 targets had a shorter median survival time compared to patients whose tumors had low expression of STAT3 targets. These data suggest that constitutively activated STAT3 in gliomas can alter the biology of these tumors, and that development of targeted STAT3 inhibitors would likely be of particular benefit in treatment of this disease.
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634710/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11179747
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search